Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer With Ritu Salani, MD, MBA, and Floor J. Backes, MD

Oncology Data Advisor™ · Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States (ACS, 2022). The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage ca...

Continue reading

Staying Up to Date on Endometrial Cancer With Ritu Salani, MD

Cancer of the uterine corpus, also called endometrial cancer, is the most common cancer of the female genital tract, with the American Cancer Society estimating that there will be 65,950 new diagnoses and 12,550 fatal cases in the United States in 2022. In this interview, Ritu Salani, MD, Director of the Division of Gynecologic Oncology at the University of California, Los Angeles (UCLA) Health, touches base on a recent activity she led, Emerging Checkpoint Inhibitor-Based Strategies for Advanced Endometrial Cancer. In addition, she discusses updates since recording the activity and why it's important for health care professionals to participate in staying up to date with the evolving landscape of endometrial cancer treatment options.  

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.